Bio-Rad Introduces StarBright Blue and StarBright Yellow Dyes to Enhance Multiplex Flow Cytometry
StarBright Blue and StarBright Yellow Dyes Conjugated to Highly Validated Antibodies for Conventional and Full Spectrum Flow Cytometry in Immunology Research
H.E.L Group appoints Allen Wang as General Manager of H.E.L China
Appointment follows successful expansion of operations in China and transition to direct sales model Supports next phase in H.E.L’s development as China becomes significant contributor to commercial growthH.E.L Group (H.E.L), a global developer
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems
MIP Discovery secures significant funding to support development of global rapid response diagnostics
Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries.
Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chr
Bio-Rad’s CFX Opus Deepwell Dx Real-Time PCR System Advances Large Reaction Volume IVD Assay Development and Diagnostic Testing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, a real-time PCR system listed with the U.S.
Pangaea Data Named “Digital Solution of the Year” by the UK Government’s Department for International Trade (DIT)
Pangaea Data, (Pangaea), provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, today announced that it has been named “Digital Solution of the Year” by the UK Government’s Department for In
Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field
Supporting Master’s student in Prof Helen Walden’s laboratory Project aims to determine USP30 structure to inform the design and discovery of novel inhibitorsDundee, UK - Ubiquigent Limited (Ubiquigent), a drug discovery and development compa
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.
Pheno Therapeutics announces worldwide license from UCB to a novel program for neurodegenerative disease
Preclinical program with potential for disease modifying therapeutic
FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production
Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines
Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that it has entered into a strategic, multi-phase collaboration with the Instituto de Biologia Experim
Astrea Bioseparations acquires Delta Precision Ltd, a leading manufacturer of chromatography columns for biomanufacturing
Cambridge, UK - Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd.
Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board
Leading expert in DUB biology and drug discovery further strengthens Ubiquigent’s DUB-focused capabilities and internal pipelineDundee, UK - Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB)
Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines.
Global Access Diagnostics joins consortium to co-develop on-farm rapid test for calf pneumonia, RaDiCal
Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, today announced the development of RaDiCal, a one-step molecular lateral flow test to enable rapid diagnosis of pneumonia, one of the most significant diseases affec
The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein
Antigen designed to support immunoassay and vaccine development applications
Shenandoah Biotechnology introduces expanded range of CTGrade recombinant proteins manufactured following cGMP practices
Shenandoah Biotechnology Inc., a FUJIFILM Irvine Scientific company and leading manufacturer of recombinant proteins, today announced it has expanded its CTGrade portfolio of cytokines and growth factors for cell and gene therapies manufactured following cGMP guidelines.
Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents
Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits. These include five single analyte biomarker kit
The Native Antigen Company strengthens senior team to support growing product portfolio
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced two key appointments to its management team.
Fujifilm invests $188 million in new cell culture media manufacturing facility
FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.
The Native Antigen Company introduces new range of influenza antigens
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the
Bio-Rad introduces Pioneer™ Antibody Discovery Platform for therapeutic development
HERCULES, Calif. — Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announces the launch of the Pioneer Antibody Discovery Platform, a new antibody discovery service specifically designed to develop best-in-class biologic candidates.